441 related articles for article (PubMed ID: 12886244)
1. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
[TBL] [Abstract][Full Text] [Related]
2. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
3. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
5. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia.
Nakao M; Yokota S; Horiike S; Taniwaki M; Kashima K; Sonoda Y; Koizumi S; Takaue Y; Matsushita T; Fujimoto T; Misawa S
Leukemia; 1996 Sep; 10(9):1463-70. PubMed ID: 8751464
[TBL] [Abstract][Full Text] [Related]
6. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
7. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods.
Taube T; Eckert C; Körner G; Henze G; Seeger K
Leuk Res; 2004 Jul; 28(7):699-706. PubMed ID: 15158091
[TBL] [Abstract][Full Text] [Related]
8. Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.
Mosad E; Hamed HB; Bakry RM; Ezz-Eldin AM; Khalifa NM
J Hematol Oncol; 2008 Oct; 1():17. PubMed ID: 18928518
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
10. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
12. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
13. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
17. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
18. [Relation between TEL-AML1 expression level and clinical characteristics as well as early response to treatment in children with acute lymphoblastic leukemia].
Li ZG; Zhao W; Gao Z; Wu MY; Zhang YH; Shi HW; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):523-7. PubMed ID: 17605858
[TBL] [Abstract][Full Text] [Related]
19. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.
Alm SJ; Engvall C; Asp J; Palmqvist L; Abrahamsson J; Fogelstrand L
Int J Lab Hematol; 2017 Apr; 39(2):121-128. PubMed ID: 28004528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]